Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 322

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 322
---
, and any incentive compensation and equity based plans that are subject to Iris Board approval of all of Iris’s other officers;

•

reviewing Iris’s executive compensation policies and plans;

•

implementing and administering Iris’s incentive compensation equity-based remuneration plans;

•

assisting management in complying with Iris’s proxy statement and annual report disclosure requirements;

<div align='center'>171</div>

TABLE OF CONTENTS

•

approving all special perquisites, special cash payments and other special compensation and benefit arrangements for Iris’s officers and employees;

•

producing a report on executive compensation to be included in Iris’s annual proxy statement; and

•

reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.

The charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser and is directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.

Compensation Committee Interlocks and Insider Participation

None of Iris’s executive officers currently serves, and in the past year has not served, as a member of the compensation committee of any entity that has one or more executive officers serving on the Iris Board.

### Code of Business Conduct and Ethics
Iris has adopted a Code of Business Conduct and Ethics applicable to our directors, officers and employees. A copy of the Code of Business Conduct and Ethics will be provided without charge upon written request to Iris’s principal executive offices. Iris intends to disclose any amendments to or waivers of certain provisions of its Code of Business Conduct and Ethics in a Current Report on Form 8-K. Please see the section of this proxy statement/prospectus entitled “ Where You Can Find More Information .”

<div align='center'>172</div>

TABLE OF CONTENTS

### BUSINESS OF IRIS

#### Introduction
We are a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. We have neither engaged in any operations unrelated to our search for business combination candidates nor generated any revenue to date.

The registration statement for our initial public offering was declared effective on March 4, 2021. On March 9, 2021